Read

Members
Client Resources
Pharmacy + Provider Resources
Drug Recalls
Events

Who we are
Our solutions
Read, watch, listen
Pharmacy
Careers

Members
Client Resources
Pharmacy + Provider Resources
Drug Recalls
Events

Home
Read, watch, listen
Read

Explore what's trending at Prime

https://www.primetherapeutics.com/w/what-s-driving-medical-benefit-spend-prime-therapeutics-trend-report-shares-new-clues Example Link

Press Releases

What's driving medical benefit spend? Prime Therapeutics trend report shares new clues

September 04, 2025

https://www.primetherapeutics.com/w/prime-presents-2025-medical-pharmacy-trend-report-webcast-on-oct-13

Events

Prime presents 2025 Medical Pharmacy Trend Report webcast on Oct. 13

September 23, 2025

https://www.primetherapeutics.com/w/high-cost-therapy-profile-september-2025 /high-cost-therapy-profile-september-2025

Research & Publications

High-Cost Therapy Profile: September 2025

September 22, 2025

https://www.primetherapeutics.com/w/expert-clinical-network-insights-september-2025 /expert-clinical-network-insights-september-2025

Research & Publications

Expert Clinical Network Insights: September 2025

September 19, 2025

The Latest

Categories

PA Sub-Categories

https://www.primetherapeutics.com/w/prime-therapeutics-leading-research-shows-only-1-in-12-remain-on-a-glp-1-drug-for-obesity-at-three-years

Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

June 25, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-highlights-industry-leading-glp-1-research-at-amcp-2025

Prime Therapeutics highlights industry-leading GLP-1 research at AMCP 2025

March 31, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-glp-1-research-year-2-cost-of-care-is-4-200-higher-for-patients-with-obesity

Prime Therapeutics GLP-1 research: Year-2 cost of care is $4,200 higher for patients with obesity

October 24, 2024

https://www.primetherapeutics.com/w/prime-therapeutics-bolsters-its-position-as-industry-leader-with-10-research-studies-at-amcp-nexus-2024

Prime Therapeutics bolsters its position as industry leader with 10 research studies at AMCP Nexus 2024

October 10, 2024

https://www.primetherapeutics.com/w/prime-continues-to-lead-industry-on-glp-1-research-1-in-7-stays-on-glp-1-drugs-for-weight-loss-after-two-years

Prime continues to lead industry on GLP-1 research: 1 in 7 stays on GLP-1 drugs for weight loss after two years

July 10, 2024

https://www.primetherapeutics.com/w/prime-therapeutics-and-magellan-rx-to-present-eight-managed-care-pharmacy-research-studies-at-amcp

Prime Therapeutics and Magellan Rx to present eight managed care pharmacy research studies at AMCP

April 11, 2024

Showing 1 to 6 of 9

Categories

PA Sub-Categories

https://www.primetherapeutics.com/w/prime-s-biosimilar-strategy-drives-optionality-for-health-plans

Prime’s biosimilar strategy drives optionality for health plans

August 07, 2025

https://www.primetherapeutics.com/w/prime-refines-the-way-it-serves-medicare-clients-and-members

Prime refines the way it serves Medicare clients and members

July 29, 2025

https://www.primetherapeutics.com/w/what-s-next-in-the-glp-1-pipeline-prime-s-clinical-team-shares-the-latest

What’s next in the GLP-1 pipeline? Prime’s clinical team shares the latest

June 18, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-recognizes-migraine-and-headache-awareness-month

Prime Therapeutics recognizes Migraine and Headache Awareness Month

June 18, 2025

https://www.primetherapeutics.com/w/prime-therapeutics-identifies-addresses-misuse-of-asthma-inhaler-prescription-with-174k-impact

Prime Therapeutics identifies, addresses misuse of asthma inhaler prescription with $174K impact

April 29, 2025

https://www.primetherapeutics.com/w/national-drug-take-back-day-prioritizing-drug-safety-at-home

National Drug Take Back Day: Prioritizing drug safety at home

April 23, 2025

Showing 1 to 6 of 61

Categories

PA Sub-Categories

https://www.primetherapeutics.com/w/prime-careers-spotlight-september-2025 /prime-careers-spotlight-september-2025

Prime Careers Spotlight: September 2025

September 17, 2025

https://www.primetherapeutics.com/w/top-3-trends-in-cystic-fibrosis-treatment

Top 3 trends in cystic fibrosis treatment

September 08, 2025

https://www.primetherapeutics.com/w/how-integrated-data-is-changing-the-way-prime-therapeutics-manages-medical-pharmacy

How integrated data is changing the way Prime Therapeutics manages medical pharmacy

September 04, 2025

https://www.primetherapeutics.com/w/a-new-era-in-liver-health-how-glp-1s-are-a-mash-treatment-breakthrough

A new era in liver health: How GLP-1s are a MASH treatment breakthrough

August 21, 2025

https://www.primetherapeutics.com/w/innovation-and-impact-mesc-2025-charts-the-future-of-medicaid-technology

Innovation and impact: MESC 2025 charts the future of Medicaid technology

August 21, 2025

https://www.primetherapeutics.com/w/rising-cancer-rates-in-younger-adults-what-health-care-payers-need-to-know

Rising cancer rates in younger adults — what health care payers need to know

August 19, 2025

Showing 1 to 6 of 141

Categories

PA Sub-Categories

https://www.primetherapeutics.com/w/prime-presents-2025-medical-pharmacy-trend-report-webcast-on-oct-13

Prime presents 2025 Medical Pharmacy Trend Report webcast on Oct. 13

September 23, 2025

https://www.primetherapeutics.com/w/prime-expert-presents-at-the-most-favored-nation-mandate-webinar

Prime expert presents at “The Most Favored Nation Mandate” webinar

September 02, 2025

https://www.primetherapeutics.com/w/prime-presents-at-national-association-of-specialty-pharmacy-nasp-annual-meeting-from-sept-14-17

Prime presents at National Association of Specialty Pharmacy (NASP) annual meeting from Sept. 14–17

August 25, 2025

https://www.primetherapeutics.com/w/prime-presents-at-isg-digital-business-summit-on-nov-14

Prime presents at ISG Digital Business Summit on Nov. 14

November 05, 2024

https://www.primetherapeutics.com/w/prime-presents-at-amcp-nexus-2024

Prime presents at AMCP Nexus 2024 on Oct. 14–17

September 30, 2024

https://www.primetherapeutics.com/w/prime-presents-at-medicaid-drug-rebate-program-mdrp-summit-2024-on-sept-23-25

Prime presents at Medicaid Drug Rebate Program (MDRP) Summit 2024 on Sept. 23–25

September 23, 2024

Showing 1 to 6 of 35

Categories

PA Sub-Categories

https://www.primetherapeutics.com/w/what-the-president-s-drug-pricing-push-means-for-pharma-payers-and-patients https://www.pharmexec.com/view/president-drug-pricing-push-payers-patients

What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients

September 11, 2025

https://www.primetherapeutics.com/w/experts-throw-cold-water-on-the-idea-that-dtc-platforms-will-meaningfully-lower-drug-prices

Experts throw cold water on the idea that DTC platforms will meaningfully lower drug prices

September 08, 2025

https://www.primetherapeutics.com/w/rising-cancer-drug-costs-calls-for-collaboration-and-value-based-care-pbmi-2025 https://www.managedhealthcareexecutive.com/view/rising-cancer-drug-costs-calls-for-collaboration-and-value-based-care-pbmi-2025

Rising Cancer Drug Costs Calls for Collaboration and Value-Based Care | PBMI 2025

September 05, 2025

https://www.primetherapeutics.com/w/cost-savings-from-glp-1-weight-loss-drugs-still-elusive-1 https://www.forbes.com/sites/joshuacohen/2025/09/03/cost-savings-from-glp-1-weight-loss-drugs-still-elusive/

Cost Savings From GLP-1 Weight Loss Drugs Still Elusive

September 03, 2025

https://www.primetherapeutics.com/w/specialty-pharmacy-continuum-glp-1s-for-everything-balancing-access-with-sustainability https://www.specialtypharmacycontinuum.com/Clinical/Article/08-25/GLP-1s-Potential-New-Uses/77960

Specialty Pharmacy Continuum: ‘GLP-1s for Everything!’: Balancing Access With Sustainability

August 15, 2025

https://www.primetherapeutics.com/w/managed-healthcare-executive-medicare-plans-face-higher-liability-from-cap-on-out-of-pocket-drug-costs https://www.managedhealthcareexecutive.com/view/medicare-plans-face-higher-liability-from-cap-on-out-of-pocket-drug-costs

Managed Healthcare Executive: Medicare Plans Face Higher Liability From Cap on Out-of-Pocket Drug Costs

August 15, 2025

Showing 1 to 6 of 116

Categories

PA Research & Publications

https://www.primetherapeutics.com/w/high-cost-therapy-profile-september-2025 /high-cost-therapy-profile-september-2025

High-Cost Therapy Profile: September 2025

September 22, 2025

https://www.primetherapeutics.com/w/expert-clinical-network-insights-september-2025 /expert-clinical-network-insights-september-2025

Expert Clinical Network Insights: September 2025

September 19, 2025

https://www.primetherapeutics.com/w/oncology-insights-september-2025 /oncology-insights-september-2025

Oncology Insights: September 2025

September 19, 2025

https://www.primetherapeutics.com/w/fda-decisions-expected-october-2025 /fda-decisions-expected-october-2025

FDA Decisions Expected: October 2025

September 17, 2025

https://www.primetherapeutics.com/w/trending-topics-drug-approvals-august-2025 /trending-topics-drug-approvals-august-2025

GLP-1 Pipeline Update: August 2025

August 28, 2025

Showing 1 to 6 of 170

Login Portals

Members and Consumers
Clients and Health Plans
Pharmacy + Provider Resources

Compliance / Legal

Privacy Policy
Notice of Privacy Practices
Terms of Use
Nondiscrimination + Languages
Subrogation

Company

About us
Careers
News
Media

Read - Prime Therapeutics

About us

Corporate social responsibility

Solutions overview

Modern technology

Drug access

Clinical solutions

Condition management

Specialty drug management

Government solutions

Single-state programs

Watch

Listen

Home Delivery

Specialty Pharmacy

Navigate to

Back

Back

Back

Back

Explore what's trending at Prime

What's driving medical benefit spend? Prime Therapeutics trend report shares new clues

Prime presents 2025 Medical Pharmacy Trend Report webcast on Oct. 13

High-Cost Therapy Profile: September 2025

Expert Clinical Network Insights: September 2025

The Latest

Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

Prime Therapeutics highlights industry-leading GLP-1 research at AMCP 2025

Prime Therapeutics GLP-1 research: Year-2 cost of care is $4,200 higher for patients with obesity

Prime Therapeutics bolsters its position as industry leader with 10 research studies at AMCP Nexus 2024

Prime continues to lead industry on GLP-1 research: 1 in 7 stays on GLP-1 drugs for weight loss after two years

Prime Therapeutics and Magellan Rx to present eight managed care pharmacy research studies at AMCP

Prime’s biosimilar strategy drives optionality for health plans

Prime refines the way it serves Medicare clients and members

What’s next in the GLP-1 pipeline? Prime’s clinical team shares the latest

Prime Therapeutics recognizes Migraine and Headache Awareness Month

Prime Therapeutics identifies, addresses misuse of asthma inhaler prescription with $174K impact

National Drug Take Back Day: Prioritizing drug safety at home

Prime Careers Spotlight: September 2025

Top 3 trends in cystic fibrosis treatment

How integrated data is changing the way Prime Therapeutics manages medical pharmacy

A new era in liver health: How GLP-1s are a MASH treatment breakthrough

Innovation and impact: MESC 2025 charts the future of Medicaid technology

Rising cancer rates in younger adults — what health care payers need to know

Prime presents 2025 Medical Pharmacy Trend Report webcast on Oct. 13

Prime expert presents at “The Most Favored Nation Mandate” webinar

Prime presents at National Association of Specialty Pharmacy (NASP) annual meeting from Sept. 14–17

Prime presents at ISG Digital Business Summit on Nov. 14

Prime presents at AMCP Nexus 2024 on Oct. 14–17

Prime presents at Medicaid Drug Rebate Program (MDRP) Summit 2024 on Sept. 23–25

What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients

Experts throw cold water on the idea that DTC platforms will meaningfully lower drug prices

Rising Cancer Drug Costs Calls for Collaboration and Value-Based Care | PBMI 2025

Cost Savings From GLP-1 Weight Loss Drugs Still Elusive

Specialty Pharmacy Continuum: ‘GLP-1s for Everything!’: Balancing Access With Sustainability

Managed Healthcare Executive: Medicare Plans Face Higher Liability From Cap on Out-of-Pocket Drug Costs

High-Cost Therapy Profile: September 2025

Expert Clinical Network Insights: September 2025

Oncology Insights: September 2025

FDA Decisions Expected: October 2025

Trending Topics & Drug Approvals: August 2025

GLP-1 Pipeline Update: August 2025

Login Portals

Compliance / Legal

Company